TCN1 Drives Malignant Progression of Pancreatic Cancer Through STAT4-Mediated Transcriptional Activation of the DUOX2/ROS Signaling Axis

Zonglin Liu, Dongsheng Ju, Ze Yu, B. Zhang, Dongbo Xue, Yongwei WangCancers 2025 · DOI

TL;DR

This study uncovers a new molecular pathway, the TCN1/STAT4/DUOX2/ROS axis, that drives the aggressive progression of pancreatic cancer. By understanding this axis, researchers have identified TCN1 as a potential biomarker for prognosis and a promising target for new therapies.

What Problem Does This Paper Address?

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, characterized by its aggressive nature and poor prognosis. Despite advances, effective treatments remain elusive, highlighting the urgent need to understand the underlying molecular mechanisms driving its progression. Identifying new biomarkers and therapeutic targets is crucial for improving patient outcomes. This paper investigates the role of transcobalamin 1 (TCN1) in PDAC, a protein traditionally known for vitamin B12 transport but with emerging roles in cancer, and aims to elucidate its contribution to PDAC pathogenesis.

Methods

The researchers employed a multi-pronged approach:

  • Bioinformatic Analysis: They analyzed public datasets (TCGA and GTEx) to identify TCN1 overexpression in PDAC and correlated it with clinical data.
  • Clinical Sample Analysis: They examined 80 clinical PDAC specimens using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) to validate TCN1 expression and its association with clinicopathological features.
  • In Vitro Studies: They used cell lines (BxPC-3 and PANC-1) with varying TCN1 levels to investigate TCN1's functional impact on proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT). This involved genetic manipulation techniques like siRNA for knockdown and plasmid transfection for overexpression.
  • In Vivo Studies: Orthotopic tumor models in nude mice were established to assess TCN1's role in tumor growth and metastasis.
  • Mechanistic Investigations:
    • Protein-Protein Interaction: Co-immunoprecipitation (Co-IP) and immunofluorescence were used to identify and confirm interactions between TCN1 and STAT4.
  • Transcriptional Regulation: Chromatin immunoprecipitation (ChIP) assays and luciferase reporter assays were employed to demonstrate STAT4's binding to the DUOX2 promoter and its role in transcriptional activation.
  • Signaling Pathway Analysis: Western blotting was used to assess the expression of key proteins involved in EMT and signaling pathways.
  • ROS Measurement: Intracellular reactive oxygen species (ROS) levels were measured using specific assays.
  • Rescue Experiments: To confirm the functional roles of STAT4, DUOX2, and ROS, rescue experiments were conducted where the effect of TCN1 modulation was reversed by manipulating the downstream components.
  • Antioxidant Treatment: The role of ROS was further validated by treating cells with antioxidants like N-acetylcysteine (NAC) and Tempol.

Datasets

  • TCGA (The Cancer Genome Atlas) and GTEx (Genotype-Tissue Expression) databases: Used for initial analysis of TCN1 expression in PDAC tissues compared to normal tissues and for correlating TCN1 expression with patient survival.
  • In-house cohort of 80 clinical PDAC samples: Used for validation of TCN1 expression levels and their association with TNM stage and pathological grade.
  • Public databases (GEPIA): Used to assess the correlation between TCN1 and DUOX2 expression.
  • Prediction databases (hTFtarget, JASPAR): Used to predict potential transcription factor binding sites for DUOX2.

Key Insights and Ideas

  • TCN1 as a PDAC Oncogene: The study firmly establishes TCN1 not just as a marker but as an active driver of PDAC malignancy, promoting critical aggressive behaviors like proliferation, migration, and invasion.
  • The STAT4 Connection: The discovery that TCN1 physically interacts with STAT4 and enhances its transcriptional activity is a major mechanistic breakthrough, linking TCN1 to a key signaling pathway.
  • DUOX2 as a Direct Target: Demonstrating that STAT4 directly binds to the DUOX2 promoter and drives its transcription provides a clear molecular link in the TCN1-driven cascade.
  • ROS as the Central Executor: The consistent finding that ROS generation is a critical downstream consequence of TCN1 activation, and that its inhibition reverses TCN1's effects, highlights ROS as a key mediator of PDAC progression.
  • A PDAC-Specific Axis: The findings suggest a cell-autonomous regulatory pathway for STAT4 in PDAC, distinct from its roles in immune or stromal cells, pointing to a unique vulnerability in PDAC cells.

Key Results

  • TCN1 Overexpression in PDAC: TCN1 is significantly overexpressed in PDAC tissues compared to normal tissues.
  • Prognostic Significance: Higher TCN1 expression is associated with advanced tumor stage, poor histological differentiation, and reduced overall survival in PDAC patients.
  • TCN1 Promotes Aggressive Phenotypes: Knockdown of TCN1 inhibits proliferation, migration, and invasion in PDAC cells, while TCN1 overexpression enhances these behaviors. This was validated in vivo, with TCN1 knockdown reducing tumor growth and metastasis.
  • STAT4-DUOX2 Link: TCN1 interacts with STAT4, leading to STAT4-mediated transcriptional activation of DUOX2.
  • DUOX2 Drives ROS Production: DUOX2 is a key enzyme that generates ROS, and its upregulation by TCN1 leads to increased intracellular ROS levels.
  • ROS Mediates EMT and Metastasis: The TCN1/STAT4/DUOX2 axis drives EMT and promotes metastasis, with ROS acting as a critical downstream effector.
  • Antioxidant Efficacy: Treatment with antioxidants (NAC and Tempol) effectively abrogated TCN1-driven oncogenic phenotypes, confirming the critical role of ROS.

Limitations and Future Work

  • Mechanistic Resolution: While the study establishes the TCN1-STAT4 interaction and its impact on DUOX2/ROS, the precise regulatory mechanism by which TCN1 influences STAT4 activity (e.g., protein stability, phosphorylation) requires further investigation.
  • Pharmacological Tools: The use of pleiotropic antioxidants (NAC and Tempol) to verify ROS's role, while effective, limits the specificity of pharmacological interventions.
  • Therapeutic Strategies: Future research should focus on developing more specific therapeutic strategies targeting the TCN1/STAT4/DUOX2/ROS axis for precision therapy in PDAC. Further investigations into protein stability and post-translational modifications of STAT4 could reveal actionable nodes for intervention.

Summary updated

Abstract

Collectively, our findings reveal a novel TCN1/STAT4/DUOX2 regulatory axis that exacerbates PDAC progression by remodeling redox homeostasis. This signaling cascade may serve as a prognostic biomarker and a potential therapeutic target for ROS-directed precision therapy in PDAC.
BibTeX
@inproceedings{liu2025tcn,
  author = {Zonglin Liu and Dongsheng Ju and Ze Yu and B. Zhang and Dongbo Xue and Yongwei Wang},
  title = {{TCN1 Drives Malignant Progression of Pancreatic Cancer Through STAT4-Mediated Transcriptional Activation of the DUOX2/ROS Signaling Axis}},
  booktitle = {Cancers},
  year = {2025},
  doi = {10.3390/cancers17203300},
}
Figure